(NOVC.DE) Stock Price, Forecast & Analysis
Europe - FRA:NOVC - DK0060534915 - Common Stock
NOVC.DE Key Statistics, Chart & Performance
The current stock price of NOVC.DE is 86.34 EUR. In the past month the price decreased by -49.3%. In the past year, price decreased by -13.99%.
NOVC.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1SAN.MI | SANOFI | 11.84 | 219.19B | ||
| SNW.DE | SANOFI | 11.85 | 219.41B | ||
| SAN.PA | SANOFI | 11.83 | 218.97B | ||
| MRK.DE | MERCK KGAA | 16.75 | 50.33B | ||
| 1MRK.MI | MERCK KGAA | 13.27 | 49.11B | ||
| UCB.BR | UCB SA | 35.61 | 44.46B | ||
| 1BAYN.MI | BAYER AG-REG | 5.68 | 27.43B | ||
| BAYN.DE | BAYER AG-REG | 5.68 | 27.45B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 26.52 | 10.93B | ||
| IPN.PA | IPSEN | 12.72 | 10.95B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 96.06 | 8.89B | ||
| VIRP.PA | VIRBAC SA | 20.56 | 2.99B |
Related stock screener links
About NOVC.DE
Company Profile
Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Info
Novo Alle 1
Bagsvaerd DK
Employees: 59337
Phone: 4544448888.0
/ NOVC.DE FAQ
What does do?
Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Can you provide the latest stock price for ?
The current stock price of NOVC.DE is 86.34 EUR. The price decreased by -2.3% in the last trading session.
Does pay dividends?
NOVC.DE does not pay a dividend.
What is the ChartMill rating of stock?
NOVC.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
On which exchange is NOVC.DE stock listed?
NOVC.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the expected growth for NOVC stock?
The Revenue of (NOVC.DE) is expected to grow by 27.56% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns ?
You can find the ownership structure of (NOVC.DE) on the Ownership tab.
NOVC.DE Technical Analysis
NOVC.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NOVC.DE. NOVC.DE scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
NOVC.DE Financial Highlights
Over the last trailing twelve months NOVC.DE reported a non-GAAP Earnings per Share(EPS) of 2. The EPS decreased by -32.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 33.4% | ||
| ROA | 23.95% | ||
| ROE | 74.32% | ||
| Debt/Equity | 0.21 |
NOVC.DE Forecast & Estimates
32 analysts have analysed NOVC.DE and the average price target is 169.94 EUR. This implies a price increase of 96.83% is expected in the next year compared to the current price of 86.34.
For the next year, analysts expect an EPS growth of 96.77% and a revenue growth 27.56% for NOVC.DE